ArticleAlimentary pharmacology & therapeutics2022

Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

Viktoria Bergqvist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.